Trust Co. of Vermont Has $335,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trust Co. of Vermont boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 199.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 470 shares of the biopharmaceutical company’s stock after buying an additional 313 shares during the quarter. Trust Co. of Vermont’s holdings in Regeneron Pharmaceuticals were worth $335,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. boosted its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the last quarter. Nvwm LLC grew its stake in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares during the last quarter. Finally, Westhampton Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 15 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $681.58 on Monday. The business’s 50-day moving average price is $738.60 and its two-hundred day moving average price is $949.32. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a P/E/G ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on REGN shares. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Citigroup lowered their price target on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.